Cannabinoids for the Neuropsychiatric Symptoms of Dementia ( NPS ) : A Systematic Review and Meta Analysis
PMID : 31835954 DOI : 10.1177 / 0706743719892717
Here is what this research means for you :
Dementia patients have doubled over 26 years from the 1990s to 2016 while 90% of them showed symptoms of Neuropsychiatric Dementia ( NPS ). This led to researches for safer therapies, including CBD ( Cannabinoids ) .
The research was aimed at the assessment of CBD efficiency and acceptability In Dementia patients. The research was designed using a Systematic review, Meta-Analysis ( Qualitative and Quantitative analysis) of clinical trials.
44 % among the volunteers were women, age 70 + with Alzheimer’s disease. While tests were conducted in Europe and North America.
Tested Compounds :
Tetrahydrocannabinol, Dronabinol, Nabilone were explored during the research
All the selected data acquired from patients was twice tested and analyzed by two researchers and guided by a third reviewer to rule out any inconsistencies in it. We extracted the data on a median of several NPS tests, test completion, and recording any side effects. Data was also pooled ( collective results of multiple studies ) using random effect models.
CBDs test results helped to improve NSP test mechanisms and tools, especially Cohen Mansfield Agitation Inventory and Neuropsychiatric Inventory.
Effects on patients :
Patients were able to tolerate the CBDs and no serious side effects were noticed, This research was strictly focused on the dosage of CBDs and the severity of dementia in patients, regardless of gender or age.
Early results have shown that cannabinoids or CBDs are effective and harmless for the treatment of Dementia ( NPS) . More versatile studies are required to find better results about real-world effectiveness.